It aims to provide crucial guidance for the standardization and optimization of IgA nephropathy diagnosis and treatment. The Guideline (Draft) emphasizes a new disease management strategy of Treat the ...

NEFECON®, as the only in-disease IgA nephropathy (IgAN) treatment has been included in the "KDIGO 2024 Clinical Practice Guideline For The Management Of Immunoglobulin A Nephropathy (IgAN) And ...

The outcome was favorable, and the glomerular filtration rate was fully restored after three months of treatment. IgA vasculitis nephritis can be severe and affect vital prognosis and renal function.

The outcome was favorable, and the glomerular filtration rate was fully restored after three months of treatment. IgA vasculitis nephritis can be severe and affect vital prognosis and renal function.

Panelists discuss how patient-reported outcomes including symptom burden, treatment-related adverse effects, preserved functionality, and impact on quality of life should be prioritized alongside ...

IgA Nephropathy (IgAN) is an autoimmune kidney disease. Without treatment, it can cause a variety of complications. Treatment focuses on disease management and slowing disease progression.

Patients with LVV and IBD present with distinct clinical characteristics, including earlier onset and more severe vascular involvement.

A single-cell analysis of nearly 18,000 white blood cells identifies a unique neutrophil subset characterized by type II ...

Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by ... randomization and received at least one dose of treatment during the double-blind period, included in ...

Panelists discuss how step-therapy for immunoglobulin A (IgA) nephropathy is evolving toward a more personalized approach, ...